Given that miR-29b seems to be an important effector of the anti-MM activity of small molecule EZH2 inhibitors, it is reasonable that the design of anti-tumor strategies targeting EZH2 should take into account the miR-29b status of tumor cells, and that upregulation of miR-29b after treatment may be likely predictive of response to these drugs. The gene discussed is EZH2; the disease is neoplasm.